Lupin receives USFDA approval for generic Ravicti oral liquid
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Once finalized, cough syrups will no longer be available for over-the-counter sale
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Subscribe To Our Newsletter & Stay Updated